Bing

SEARCH HISTORY

Celldex Therapeutics (NASDAQ: CLDX ) is a clinical-stage biopharma focusing primarily ... short-sellers have piled into this stock this year. And perhaps correlated with this rising short interest, Celldex shares have fallen a noteworthy 28% year to ...
The Motley Fool · 7/7/2014
Celldex Therapeutics (NASDAQ:CLDX) CFO Avery W. Catlin sold 25,000 shares of Celldex Therapeutics stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.59, for a total transaction of $614,750.00. Following the ...
wkrb13.com · 6/17/2015
The stock market closed really well on Tuesday ... Celldex Therapeutics, Inc. (NASDAQ:CLDX) is coming along nicely. On Tuesday, it was up 25 cents to 25.73, or 1%, on 1.2 million shares. When the base was forming in early 2014, a swing was put on it ...
investing.com · 7/8/2015
Celldex Therapeutics (NASDAQ:CLDX) CFO Avery W. Catlin sold 25,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $24.59, for a total value of $614 …
sleekmoney.com · 6/17/2015
Celldex Therapeutics Inc. (CLDX) was one of the Russell 2000's biggest losers for Monday June 29 as the stock slid 5.43% to $23.67, a loss of $-1.36 per share. Starting at an opening price of $24.50 a share, the stock traded between $23.62 and $25.00 over ...
Equities · 6/30/2015
Celldex Therapeutics, Inc. (CLDX), a clinical-stage company ... and the company reported a loss of 36 cents per share (these figures take out stock option expenses). Revenue: Revenues surpassed year-ago figures. Celldex posted revenues of $1.5 million ...
ZACKS · 2/24/2015
According to SmarterAnalyst, the analyst reiterated an Outperform rating on the stock with a $26 price target. Peaker noted “This designation now gives CLDX more intensive FDA guidance on the development of rindo, which we believe will become …
Benzinga · 2/24/2015
New York, NY - (ACCESSWIRE) - 11/11/2013 - Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding Gogo Inc. (NASDAQ:GOGO), Celldex Therapeutics, Inc. (NASDAQ:CLDX), ViroPharma Inc. (NASDAQ:VPHM), and Arena …
4 Traders · 11/11/2013
Celldex Therapeutics, Inc. CLDX, +0.13% today announced the pricing of an underwritten public offering of 7,250,000 shares of its common stock, offered at a price to the public of $24.00 per share for an aggregate offering of $174.0 million of common stock.
Market Watch · 2/25/2015
Celldex Therapeutics, Inc. (Nasdaq: CLDX) 17.6% HIGHER; On Friday, the company announced an interim update from the Phase 2 ReACT study of rindopepimut in EGFRvIII-positive glioblastoma (GBM). The ReACT results demonstrate clear signs of …
StreetInsider · 11/17/2014